Precision BioSciences to Regain Programs After Prevail Team-Up Ends
By Dean Seal
Precision BioSciences expects to get three programs back from Prevail Therapeutics after a gene-editing collaboration between the two companies ended.
The advanced gene-editing company said Tuesday that it has exercised its option to regain rights for the programs after Prevail, a subsidiary of Eli Lilly, elected to conclude the collaboration that started up in January 2021.
The two companies advanced three programs from concept toward clinical candidates during that time, Chief Executive Michael Amoroso said.
Given the strong proof-of-concept data generated so far, Precision is looking into opportunities to develop the returned programs independently or in partnership with others, it said.
The return of the programs isn't expected to impact Precision's near-term clinical priorities, the company said.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
April 16, 2024 17:07 ET (21:07 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track